Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of artesunate to preparation of anti-osteoclast differentiation medicine

An osteoclast and artesunate technology, which can be used in drug combinations, bone diseases, pharmaceutical formulations, etc., can solve problems such as osteonecrosis of the jaw and high price

Active Publication Date: 2015-09-23
SOUTHERN MEDICAL UNIVERSITY
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, most bisphosphonates need to be administered by injection, which is likely to cause serious adverse reactions such as osteonecrosis of the jaw; while denosumab, a biological antibody preparation targeting the osteoclast activating factor RANKL, needs to be administered by subcutaneous injection and is more expensive

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of artesunate to preparation of anti-osteoclast differentiation medicine
  • Application of artesunate to preparation of anti-osteoclast differentiation medicine
  • Application of artesunate to preparation of anti-osteoclast differentiation medicine

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0027] Experimental example 1. The cell survival effect of artesunate on RAW264.7 cells:

[0028] RAW264.7 cells 1×10 4 or 1×10 3 Each well was planted in a 96-well plate, and the drug artesunate was added after overnight at a concentration of 3.125 μM, 6.25 μM, and 12.5 μM. 3 replicate wells in each group. After incubating for 8h, 24h, 48h, and 7d respectively, remove the supernatant, add 0.5mg / ml MTT 100μl to each well, incubate in a 37°C incubator for 4h, discard the supernatant, add DMSO 150μl, shake for 10 minutes , Measure the absorbance at 450 nm with a Genios Pro Tecan microplate reader.

[0029] Depend on figure 1 It can be seen that the in vitro concentration ≤ 12.5 μM has no significant effect on the survival of RAW264.7 cells.

experiment example 2

[0030] Experimental example 2. The effect on the differentiation of osteoclast precursor Raw264.7 cells into osteoclasts:

[0031] Select RAW264.7 cells in good growth state and press 1×10 3 Inoculate in a 96-well plate at a density of / ml, and add 100 μl / well of DMEM medium containing 10% FBS, 100 U / ml penicillin G and 100 μg / ml streptomycin, at 37°C, 5% CO 2 Incubator incubation. After the cells were stabilized overnight, in addition to the negative control group (Control group), the positive control group (RANKL group) and the drug group were all added RANKL with a final concentration of 100 ng / ml. 6.25 μM and 12.5 μM (respectively Art1.56 μM group, Art 3.125 μM group, Art 6.25 μM group and Art 12.5 μM group), each group had 3 replicate wells. Change the medium every 2 days. On the 4th day of induction, TRAP staining was observed, photographed under a microscope, and counted as osteoclasts with more than 3 nuclei positive for TRAP. Such as figure 2 .

experiment example 3

[0032] Experimental example 3. Effect on the differentiation of mouse bone marrow macrophages (BMMs) into osteoclasts:

[0033] Take the femur and tibia of C57BL / 6 mice, peel off the muscle and cut off both ends, use a syringe to absorb ice-cold a-MEM and repeatedly wash the bone marrow cavity of the femur and tibia until the bone marrow cavity turns white. %CO 2 After 30 minutes in the incubator, the supernatant suspension was taken. cells by 2 x 10 5 / ml density inoculated in 96-well plate, in addition to the negative control group (Control group), the positive control group (RANKL group) and the drug group were all added M-CSF and RANKL, the final concentration was 50ng / ml, and the drug group was added green Artesunate 1.56 μM, 3.125 μM, 6.25 μM and 12.5 μM (Art1.56 μM group, Art 3.125 μM group, Art 6.25 μM group and Art 12.5 μM group respectively), each group had 3 replicate wells. Change the medium every 2 days. On the 4th day of induction, TRAP staining was observed,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of artesunate to preparation of an anti-osteoclast differentiation medicine. Experiments prove that the artesunate can directly and obviously inhibit in-vitro RANKL (osteoclast differentiation factor) to induce osteoclast precursor cell differentiation to form osteoclasts; the artesunate inhibits the osteoclasts to absorb bone substances; the osteoclasts are activated in vivo to obviously improve bone loss of a bone destruction-causing classical model, i.e. ovary-cut osteoporosis mouse; the artesunate has the advantages of convenience in taking, economy, effectiveness and the like; the artesunate has direct and obvious inhibiting characteristic on osteoclastogenesis and osteoclastic activity, so that the artesunate can serve as an osteoclast differentiation inhibiting medicine and is applied to diseases which are treated by the osteoclast differentiation inhibiting medicine; the artesunate serves as an active medicine precursor and is used for studying and developing the osteoclast differentiation inhibiting medicine.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a new drug classification application of artesunate. Background technique [0002] The stabilization of bone metabolism requires a dynamic balance and coupling between bone resorption mediated by osteoclasts (OCs) and bone formation mediated by osteoblasts (OBs), which maintain function in healthy individuals Balance, and once the balance is broken, it may lead to the occurrence of bone diseases. [0003] Osteoclasts are the only cells in the body responsible for bone resorption. It can differentiate into functional mature osteoclasts from osteoclast precursor cells after activation. Because differentiated and mature osteoclasts can absorb bone, their excessive activation can cause bone loss, osteoporosis, fracture pain, secondary reactive bone hyperplasia, and even disability. There are many diseases related to the overactivation of osteoclasts. The classic one is postmenopausal osteo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/357A61P19/08A61P19/10
Inventor 李晓娟曾祥周王铿张悦阳陶磊刘叔文
Owner SOUTHERN MEDICAL UNIVERSITY